Key Takeaways:
- Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome.
- Patients come to Evvy with active vaginal symptoms or fertility challenges that standard-of-care testing has failed to explain.
- In the US, vaginal symptoms are a leading reason women seek healthcare.
Evvy has built the world’s largest vaginal microbiome dataset to improve outcomes across the female lifespan.
WHO: Founded by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy is the leading vaginal microbiome platform, serving over 100,000 patients and 3,000 practitioners with comprehensive at-home testing, personalized treatment, and longitudinal biomarker tracking. Every Evvy test is powered by Clinical Laboratory Improvement Amendments (CLIA)-certified, New York State Clinical Laboratory Evaluation Program (CLEP)-approved metagenomic sequencing; ordered and interpreted by licensed clinicians; and matched with prescription treatment plans tailored to each patient’s results and health history where relevant. The company’s at-home Vaginal Health Test analyzes more than 700 bacteria and fungi from a vaginal swab. Priced at $159 for a single test or $129 per test through a membership.
WHY: The funding will expand Evvy’s vaginal microbiome platform into reproductive healthcare, starting with fertility and IVF, and scale EvvyAI, the data and artificial intelligence platform underlying its vaginal healthcare business.
IN THEIR OWN WORDS: Jacob Vogelstein, co-founder and Managing Partner at Catalio Capital, was drawn to Evvy because of the depth and uniqueness of its data and its AI infrastructure. “Its combination of proprietary data, clinical evidence and a...
